<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992706</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 92/08</org_study_id>
    <secondary_id>SWS-SAKK-92/08</secondary_id>
    <secondary_id>EU-20978</secondary_id>
    <secondary_id>CDR0000652808</secondary_id>
    <nct_id>NCT00992706</nct_id>
  </id_info>
  <brief_title>F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer</brief_title>
  <official_title>Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women
      receiving doxorubicin hydrochloride liposome for metastatic breast cancer.

      PURPOSE: This randomized phase III trial is studying F511 cream to see how well it works
      compared with a placebo cream in preventing palmar-plantar erythrodysesthesia in patients
      receiving doxorubicin hydrochloride liposome for metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the effects of F511 cream on the occurrence of palmar-plantar
           erythrodysesthesia (PPE) in patients with metastatic breast cancer treated with
           pegylated liposomal doxorubicin hydrochloride.

      OUTLINE: This is a multicenter study.

      Patients receive pegylated liposomal doxorubicin hydrochloride according to local practice on
      1, 2, or 4 weeks course schedules with at least 10 mg/m^2 per week allowed.

      Patients apply F511 cream on one side, hand and foot and the corresponding placebo on the
      other side hand and foot once daily (the morning) during the first week of the first
      pegylated liposomal doxorubicin hydrochloride treatment only, then once daily, three times
      per week thereafter. Treatment continues throughout chemotherapy administration in the
      absence of palmar-plantar erythrodysesthesia (PPE) ≥ grade 2

      After completion of study therapy, patients are followed for 30 days. Patients with PPE ≥
      grade 2 are followed until the PPE resolves to ≤ grade 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Palmar-plantar erythrodysesthesia (PPE, hand-foot syndrome, HFS) grade ≥ 2</measure>
    <time_frame>Until PPE grade ≥2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome</measure>
    <time_frame>Until PPE grade ≥2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse skin reaction to local therapy</measure>
    <time_frame>Until PPE grade ≥2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of symptom relief</measure>
    <time_frame>Until PPE grade ≥2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of PPE grade ≥ 2</measure>
    <time_frame>Until PPE grade ≥2</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Palmar-plantar Erythrodysesthesia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiperspirant cream F511</intervention_name>
    <description>Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of metastatic breast cancer

               -  No cutaneous metastases on hands or feet

          -  Pegylated liposomal doxorubicin hydrochloride monotherapy is indicated according to
             the local investigator

               -  Planned dose at least 10 mg/m^2 per week

          -  No sign of palmar-plantar erythrodysesthesia (PPE) at study entry

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Able to apply topical medication (cream) or provide for another person to apply cream

          -  Not pregnant or breastfeeding

          -  Fertile patients must use effective contraception during trial participation and for 1
             month after completion

          -  Negative pregnancy test

          -  Compliant and geographically proximal in order to allow proper evaluation and
             follow-up

          -  No dermatologic conditions (e.g., psoriasis) that, in the opinion of the physician,
             may affect the hands or feet or may complicate evaluation during study treatment

          -  No known allergy or hypersensitivity to F511 cream

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 30 days since prior and no concurrent treatment with other experimental
             drugs or anticancer therapy

          -  More than 30 days since prior and no concurrent treatment on another clinical trial

          -  No concurrent local use of other ointments or creams for hands or feet other than
             Excipial Repair®
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ruhstaller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Buelach</name>
      <address>
        <city>Bulach</city>
        <zip>CH-8180</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Schaffhausen</name>
      <address>
        <city>Schaffhausen</city>
        <zip>CH-8200</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Central des Hopitaux Valaisans</name>
      <address>
        <city>Sion</city>
        <zip>CH-1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palmar-plantar erythrodysesthesia</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

